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methodology. These have resulted in signiﬁcant clinical trial heteroge-
neity. Of the 16 studies included by Shen, 1 was blinded, 5 were retro-
spective, and there was variability in CD4/CD8 ratio cut-points and
sarcoidosis diagnostic criteria. Signiﬁcant heterogeneity still existed
when the authors performed a sensitivity analysis of prospective studies
with low risk of bias.The recent meta-analysis in EBioMedicine by Shen and colleagues is
the ﬁrst to report a systematic analysis of the diagnostic performance
of bronchoalveolar lavage ﬂuid (BALF) CD4/CD8 ratios in sarcoidosis
(Shen et al., 2016). Their results are consistent with numerous studies
and BAL guidelines over the last 2 decades which have shown that ele-
vated CD4/CD8 ratios in BALF lack sufﬁcient sensitivity and speciﬁcity
needed to replace histologic conﬁrmation of sarcoidosis (Meyer et al.,
2012).
Where does the use of the BALF lymphocyte ratio fall in the diagnos-
tic pathway for sarcoidosis? One could take the position previously sug-
gested by Costabel in 1997, who argued that performing BAL as a ﬁrst
step could conﬁrm the diagnosis in themajority of patients, and obviate
the need for those patients to undergo more invasive and risky biopsy
procedures (Costabel, 1997). However, based on the pooled speciﬁcity
of 83% reported by Shen and colleagues, this approach fails to meet
one of the primary tenets of diagnosing sarcoidosis, namely the exclu-
sion of alternative diagnoses (Statement on Sarcoidosis, 1999).
More recently, the use of endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA) has gained favor at
most centers for the diagnosis of sarcoidosis. It has a low rate of adverse
events, and a recent meta-analysis reported pooled sensitivity of 84%
and speciﬁcity of 100% (Gupta et al., 2014; Trisolini et al., 2015). Al-
though TBNA is superior to the performance of the CD4/CD8 ratio, it re-
quires the presence ofmediastinal lymphadenopathy.When a CD4/CD8
ratio is considered for cases in which EBUS is negative or not available,
practitioners should be aware of factors that can alter BALF CD4/CD8 ra-
tios, including active smoking and advanced age. In addition, BALF CD4/
CD8 ratio is lower in more advanced radiographic stages of sarcoidosis
(Danila et al., 2008).
Sarcoidosis is considered an orphan disease. However, compared to
many other orphan diseases that have many diagnostic tools and treat-
ments in development, sarcoidosis has a relative lack of guidelines,om.2016.04.024.
. This is an open access article underinconsistent clinical practice across institutions, and variation in study
For a path forward, the sarcoidosis scientiﬁc community should
work for better diagnostic tools, a better understanding of pathogenesis
that might alter therapeutic targets, and build consistent practices
across centers. Collaboration and data sharing can then result in more
reliable conclusions and progress in sarcoidosis. As we leave the CD4/
CD8 ratio behind, the need for effective diagnostic biomarkers has
never been higher.Disclosure
The author declared no conﬂicts of interest.References
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